GLENMARK / NSE / Biotechnology & Drugs
Glenmark Pharmaceuticals
1Y Price Trend
Key Information
Recommendations
RatingStrong Buy
Target High2,471.05
Target Low1,448.5
Target Mean1.78
Target Median97.22
Risk Metrics
Overall RiskBalanced risk
Board Risk31.38
Key Analysis
Overall score, performance score, return rating, defensive, aggressive, and balanced views.
Download appProjection Analytics
Best-case, base-case, worst-case, and dynamic AI projection views.
Download appLatest stock news
Glenmark Consolidated March 2026 Net Sales at Rs 3,770.59 crore, up 15.8% Y-o-Y Moneycontrol.com
Number of shareholders of Glenmark Pharmaceuticals Limited – NSE:GLENMARK TradingView
Glenmark Pharmaceuticals Ltd. is Rated Strong Buy Markets Mojo
Glenmark Pharmaceuticals Q4 FY26: Exceptional Quarter Marred by Sequential Decline Markets Mojo
Glenmark Pharmaceuticals appoints Ajay Jajoo as Group VP & Global Corporate Controller Exchange4Media
Glenmark Pharma targets ₹18,000 crore revenue by FY27 on broad-based global growth CNBC TV18
Buy Glenmark Pharma; target of Rs 2610: Motilal Oswal Moneycontrol.com
Glenmark Pharmaceuticals Ltd. Technical Momentum Shifts Amid Mixed Indicator Signals Markets Mojo
© SharekeyX | Rusaka Technologies 2024-2026

